Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MAZE
MAZE THERAPEUTICS, INC.
NASDAQ
$27.44
▼ DOWN 4.06% (-1.16)

KEY STATISTICS

Market Cap$1.52 B
52w High$53.65
52w Low$14.16
Dividend Yield—
Frequency—
P/E-10.85
Volume250.05K
Shares Out.55.35M

COMPANY

LEADERSHIP

Jason V. Coloma
CHIEF EXECUTIVE
Jason V. Coloma

COMPENSATION 2026

Salary$629,167
Stock Awards$2,367,000
Incentive Plan Pay$457,600
All Other Comp.$4,500
Total$3,458,267

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 31, 2025
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
141

PRICE TARGET

Target High$97.00
Target Low$64.00
Target Median$80.50
Target Consensus$80.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$333.33K
NOV
5
THU

PRICE

$27.44 ▼ DOWN 4.06% (−$1.16)
$27.60$28.00$28.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM27.44

About Maze Therapeutics, Inc.

https://www.mazetx.com ↗

Maze Therapeutics, a South San Francisco-based biotech founded in 2017, develops precision small molecule medicines for renal, cardiovascular, metabolic diseases, and obesity, with lead programs in phase I and II trials targeting APOL1 kidney dise...

INDUSTRY

Biotechnology

A PRODUCT MAZE THERAPEUTICS, INC. IS KNOWN FOR

MZE829
MZE829

MZE829 is an investigational oral APOL1 inhibitor developed for APOL1-mediated kidney disease, currently in Phase 2 with initial data expected in Q1 2026.

COMPETITORS

COMPETITOR
BEAM COMPARE
RARE COMPARE
SRPT COMPARE
VRTX COMPARE

Revenue by Geography

MapREGIONQ1-2026
UNITED STATES$20M

ETFS HOLDING THIS STOCK

ETFS HOLDING
103
LISTED HERE
19
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M
XSU.TO
0.03% · 908.3K
XPH
1.65% · 339.1K
SCHA
0.02% · 133.0K
TCAF
0.04% · 129.2K
SBIO
0.78% · 68.3K
FESM
0.01% · 34.5K
XRSU.L
0.03% · 32.3K
RSSL
0.03% · 16.8K
GSSC
0.03% · 13.1K
BBC
0.71% · 13.0K
PILL
1.11% · 9.6K
DFMC
0.00% · 8.8K
BBSC
0.03% · 8.3K
PRFZ
0.01% · 6.3K
BIB
0.05% · 2.0K
AVSU
0.01% · 1.1K
USFMDN.MX
0.00% · 124
ESSC
0.00% · 10

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.01%
HOLDERS
186
TOP 12 OF 186 · RANKED BY POSITION SIZE
Trv Gp Iv, LLC
6.1M sh · $157.5M
Frazier Life Sciences Management, L.P.
4.6M sh · $189.22M
Deep Track Capital, LP
4.2M sh · $175.93M
Arch Venture Management, LLC
4.1M sh · $170.69M
Janus Henderson Group Plc
3.1M sh · $130.2M
Paradigm Biocapital Advisors LP
2.7M sh · $81.92M
Blackrock, Inc.
2.6M sh · $76.73M
Alphabet Inc.
2.4M sh · $62.56M
Ah Capital Management, L.L.C.
1.7M sh · $50.81M
Vanguard Group Inc
1.7M sh · $70.31M
Matrix Capital Management Company, LP
1.7M sh · $42.88M
Vr Adviser, LLC
1.6M sh · $47.82M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kornowski Sophie
Purchase · 36.0K shares
2026-08-13
★
DIRECTOR
Johnson Paula A
Purchase · 36.0K shares
2026-08-13
★
Kornowski Sophie
— · —
2026-08-13
★
Johnson Paula A
— · —
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
BTIG BUY Truist Securities BUY JP Morgan OVERWEIGHT HC Wainwright & Co. BUY Wedbush OUTPERFORM Guggenheim BUY

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
IMNM$27.57COMPARE
BCRX$9.82COMPARE
PHVS$35.32COMPARE
TRVI$16.79COMPARE
ZYME$28.27COMPARE
NTLA$12.87COMPARE
WVE$5.04COMPARE